631 related articles for article (PubMed ID: 33663399)
1. Prognostic value of the micronucleus assay for clinical endpoints in neoadjuvant radiochemotherapy for rectal cancer.
Dröge LH; Hennies S; Lorenzen S; Conradi LC; Quack H; Liersch T; Helms C; Frank MA; Schirmer MA; Rave-Fränk M; Beißbarth T; Wolff HA
BMC Cancer; 2021 Mar; 21(1):219. PubMed ID: 33663399
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the micronucleus and chromosome aberration techniques for the documentation of cytogenetic damage in radiochemotherapy-treated patients with rectal cancer.
Wolff HA; Hennies S; Herrmann MK; Rave-Fränk M; Eickelmann D; Virsik P; Jung K; Schirmer M; Ghadimi M; Hess CF; Hermann RM; Christiansen H
Strahlenther Onkol; 2011 Jan; 187(1):52-8. PubMed ID: 21234528
[TBL] [Abstract][Full Text] [Related]
3. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
4. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer.
Wolff HA; Conradi LC; Schirmer M; Beissbarth T; Sprenger T; Rave-Fränk M; Hennies S; Hess CF; Becker H; Christiansen H; Liersch T
Oncologist; 2011; 16(5):621-31. PubMed ID: 21558132
[TBL] [Abstract][Full Text] [Related]
5. Enrichment of CD133-expressing cells in rectal cancers treated with preoperative radiochemotherapy is an independent marker for metastasis and survival.
Sprenger T; Conradi LC; Beissbarth T; Ermert H; Homayounfar K; Middel P; Rüschoff J; Wolff HA; Schüler P; Ghadimi BM; Rödel C; Becker H; Rödel F; Liersch T
Cancer; 2013 Jan; 119(1):26-35. PubMed ID: 22736392
[TBL] [Abstract][Full Text] [Related]
6. Association between radiation dose and pathological complete response after preoperative radiochemotherapy in esophageal squamous cell cancer.
Ordu AD; Nieder C; Geinitz H; Scherer V; Kup PG; Schuster T; Combs SE; Fakhrian K
Anticancer Res; 2014 Dec; 34(12):7255-61. PubMed ID: 25503157
[TBL] [Abstract][Full Text] [Related]
7. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer.
Wong SJ; Moughan J; Meropol NJ; Anne PR; Kachnic LA; Rashid A; Watson JC; Mitchell EP; Pollock J; Lee RJ; Haddock M; Erickson BA; Willett CG
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):116-23. PubMed ID: 25446610
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood lymphocyte decrease and micronucleus yields during radiotherapy.
Catena C; Parasacchi P; Conti D; Sgura A; Trenta G; Righi E; Trinci MM; Trinci M
Int J Radiat Biol; 1997 Nov; 72(5):575-85. PubMed ID: 9374437
[TBL] [Abstract][Full Text] [Related]
9. Preoperative radiochemotherapy in locally advanced or recurrent rectal cancer: regional radiofrequency hyperthermia correlates with clinical parameters.
Rau B; Wust P; Tilly W; Gellermann J; Harder C; Riess H; Budach V; Felix R; Schlag PM
Int J Radiat Oncol Biol Phys; 2000 Sep; 48(2):381-91. PubMed ID: 10974451
[TBL] [Abstract][Full Text] [Related]
10. Impact of age on the efficacy of oxaliplatin in the preoperative chemoradiotherapy and adjuvant chemotherapy of rectal cancer: a post hoc analysis of the CAO/ARO/AIO-04 phase III trial.
Hofheinz RD; Arnold D; Fokas E; Kaufmann M; Hothorn T; Folprecht G; Fietkau R; Hohenberger W; Ghadimi M; Liersch T; Grabenbauer GG; Sauer R; Rödel C; Graeven U;
Ann Oncol; 2018 Aug; 29(8):1793-1799. PubMed ID: 29873684
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
12. T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
Martijnse IS; Dudink RL; Kusters M; Vermeer TA; West NP; Nieuwenhuijzen GA; van Lijnschoten I; Martijn H; Creemers GJ; Lemmens VE; van de Velde CJ; Sebag-Montefiore D; Glynne-Jones R; Quirke P; Rutten HJ
Ann Surg Oncol; 2012 Feb; 19(2):392-401. PubMed ID: 21792506
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94.
Sauer R; Fietkau R; Wittekind C; Rödel C; Martus P; Hohenberger W; Tschmelitsch J; Sabitzer H; Karstens JH; Becker H; Hess C; Raab R;
Colorectal Dis; 2003 Sep; 5(5):406-15. PubMed ID: 12925071
[TBL] [Abstract][Full Text] [Related]
14. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications.
Dellas K; Buller J; Görtz GJ; Richter M; Höhler T; Arnold D; Keck T; Dunst J; Zühlke H
Ann Surg Oncol; 2014 Apr; 21(4):1352-60. PubMed ID: 24306667
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-institutional phase II study (KROG 04-01).
Lee JH; Kim DY; Nam TK; Yoon SC; Lee DS; Park JW; Oh JH; Chang HJ; Yoon MS; Jeong JU; Jang HS
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):955-61. PubMed ID: 22537540
[TBL] [Abstract][Full Text] [Related]
16. The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.
Crane CH; Skibber JM; Birnbaum EH; Feig BW; Singh AK; Delclos ME; Lin EH; Fleshman JW; Thames HD; Kodner IJ; Lockett MA; Picus J; Phan T; Chandra A; Janjan NA; Read TE; Myerson RJ
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):84-9. PubMed ID: 12909219
[TBL] [Abstract][Full Text] [Related]
17. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
18. [Rectal cancer: current status of multimodal therapy--when and how?].
Gaedcke J; Liersch T; Hess C; Becker H; Rödel C; Ghadimi BM
Zentralbl Chir; 2011 Aug; 136(4):334-42. PubMed ID: 21863511
[TBL] [Abstract][Full Text] [Related]
19. The increment of micronucleus frequency in cervical carcinoma during irradiation in vivo and its prognostic value for tumour radiocurability.
Widel M; Jedruś S; Owczarek S; Konopacka M; Lubecka B; Kołosza Z
Br J Cancer; 1999 Jul; 80(10):1599-607. PubMed ID: 10408406
[TBL] [Abstract][Full Text] [Related]
20. Cytogenetic damage of radiotherapy in long-term head and neck cancer survivors.
Unal D; Kiraz A; Avci D; Tasdemir A; Unal TD; Cagli S; Eroglu C; Yuce I; Ozcan I; Kaplan B
Int J Radiat Biol; 2016 Jul; 92(7):364-70. PubMed ID: 27113979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
